biostudies-literatureJiang XShenzhen Medical Research FundsBasic and Applied Basic Research Foundation of Guangdong ProvinceNational Natural Science Foundation of ChinaNatural Science Foundation of Guangdong ProvinceChina Postdoctoral Science FoundationChina Postdoctoral Innovation Talent Support ProgramNational Key Research and Development Program of Chinae2406688https://www.ebi.ac.uk/biostudies/studies/S-EPMC11653702biostudies-literatureUnknown11(47)In epithelial ovarian cancer (EOC), platinum resistance, potentially mediated by cancer stem cells (CSCs), often leads to relapse and treatment failure. Here, the role of spindle pole body component 25 (SPC25) as a key determinant promoting stemness and platinum resistance in EOC cells, with its expression being correlated with adverse clinical outcomes is delineated. Mechanistically, SPC25 acts as a scaffolding platform, orchestrating the assembly of an SPC25/RIOK1/MYH9 trimeric complex, triggering RIOK1-mediated phosphorylation of MYH9 at Ser1943. This prompts MYH9 to disengage from the cytoskeleton, augmenting its nuclear accumulation, thus potentiating CTNNB1 transcription and subsequent activation of Wnt/β-catenin signaling. CBP1, a competitive inhibitory peptide, can disrupt the formAdvanced science (Weinheim, Baden-Wurttemberg, Germany)Targeting the SPC25/RIOK1/MYH9 Axis to Overcome Tumor Stemness and Platinum Resistance in Epithelial Ovarian Cancer.PMC1165370281902675A2303050BX202304412021A15150124762023M734041823031572023A151511087182203113823300822020YFA050940082173302815300822021A15150103338203007882171955823733692023A1515012746Zou HKong LPan YLi JDeng PYang MHe LChen BZhang WSong LLi YHuang SLi ZWang RZhang YJiang XShi DOuyang YChen XfalseTargeting the SPC25/RIOK1/MYH9 Axis to Overcome Tumor Stemness and Platinum Resistance in Epithelial Ovarian Cancer.In epithelial ovarian cancer (EOC), platinum resistance, potentially mediated by cancer stem cells (CSCs), often leads to relapse and treatment failure. Here, the role of spindle pole body component 25 (SPC25) as a key determinant promoting stemness and platinum resistance in EOC cells, with its expression being correlated with adverse clinical outcomes is delineated. Mechanistically, SPC25 acts as a scaffolding platform, orchestrating the assembly of an SPC25/RIOK1/MYH9 trimeric complex, triggering RIOK1-mediated phosphorylation of MYH9 at Ser1943. This prompts MYH9 to disengage from the cytoskeleton, augmenting its nuclear accumulation, thus potentiating CTNNB1 transcription and subsequent activation of Wnt/β-catenin signaling. CBP1, a competitive inhibitory peptide, can disrupt the form2024-01-01T00:00:00Z2024 Dec2025-04-26T17:04:03.817Z2025-04-06T15:25:52.715ZS-EPMC116537023948879010.1002/advs.202406688